GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

GORTEC-Cancer-Trial

More Like This

PR Newswire associated0

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

PR Newswire associated0

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

PR Newswire associated0

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Novotech Unveils 2024 Report on Global Gastric Cancer Clinical Trials and Cutting-Edge Therapeutics

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

ASTRAZENECA’S IMFINZI (DURVALUMAB) RECOMMENDED BY NICE FOLLOWING MHRA APPROVAL AS FIRST IMMUNOTHERAPY IN COMBINATION WITH PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025